Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Contact lens legislation

This article was originally published in The Gray Sheet

Executive Summary

California Governor Gray Davis (D) signs bill Sept. 23 requiring ophthalmologists and optometrists to release contact lens prescriptions to patients. Sponsored by Lou Correa (D-Anaheim), AB 2020 is expected to help consumers buy their contacts through discount stores, mail order and online distributors. The bill also provides safeguards by requiring a valid prescription with an expiration date. On Sept. 4, lens maker J&J/Vistakon met with FDA, along with 1-800-Contacts and state attorneys general from Baltimore and New York, to discuss the firm's concerns about adequate eye care for lens wearers buying through alternative sources. The Federal Trade Commission will examine the issue during its Oct. 8-10 Internet anti-competition workshop in Washington, D.C. (1"The Gray Sheet" July 22, 2002, p. 11)...

You may also be interested in...

FTC, Contact Lens Stakeholders Mull Federal Prescription Verification Laws

The Federal Trade Commission is taking a closer look at how potential national rules for contact lens prescription verification may favor Internet eyecare sellers or traditional manufacturers

Internet Anti-Competition Project Brings Devices, Contacts Under FTC’s Eye

The Federal Trade Commission will highlight contact lens and other medical supply industries during an upcoming public workshop exploring possible anti-competitive efforts that restrict e-commerce

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts